Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-10. Numbers and descriptions here follow the published literature rather than marketing material.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
=== Accelerator mass spectrometry === HVEC tandems enabled accelerator mass spectrometry (AMS), a technique that transformed radiocarbon dating and created new applications across multiple fields. In May 1977, researchers at the University of Rochester used an HVEC MP tandem to demonstrate that carbon-14 atoms could be detected directly in milligram-scale samples—compared to the 10–100 grams required by conventional decay counting. The tandem configuration exploited a key property: nitrogen-14, the primary interference in conventional dating, forms no stable negative ions and cannot survive acceleration through the system, eliminating a major source of contamination. The reduction in sample size made radiocarbon dating applicable to precious artifacts and specimens where destructive sampling had been prohibitive. Tandem machines also extended the practical range of radiocarbon dating from approximately 40,000 to potentially 100,000 years. Beyond radiocarbon applications, AMS expanded into hydrology, geoscience, biomedicine, archaeology, and paleoclimatology.
=== Mail and other parcel services === The government-owned South African Post Office (SAPO) is the primary provider of letter delivery. However, as in other countries, this means of delivering information has declined as digital communications have become preferred by many. In 2025, SAPO processed 142.7 million pieces of mail. PostNet South Africa operates the local master franchise of American company PostNet. As of 2026, there are over 500 owner-operated PostNet locations across South Africa. These outlets offer services including mailboxes, and both local and international parcel delivery. Courier partners include DHL and Aramex. Various companies operate automated parcel locker facilities and/or staffed pickup points inside retail outlets, in South Africa's major cities. These include Pargo, Bob Box, and PUDO (which is owned by The Courier Guy).
== External links == P. Romano, C. Fiore, M. Paraggio, M. Caruso, A. Capece "Function of yeast species and strains in wine flavour". Archived 2015-06-06 at the Wayback Machine. International Journal of Food Microbiology 86 (2003). pp. 169–180.
where d is the distance between the incenter and the circumcenter. In the latter double inequality, the first part holds with equality if and only if the triangle is isosceles with an apex angle of at least 60°, and the last part holds with equality if and only if the triangle is isosceles with an apex angle of at most 60°. Thus both are equalities if and only if the triangle is equilateral. We also have for any side a
Sources: en.wikipedia.org
=== Magnetic confinement fusion === MHD describes a wide range of physical phenomena occurring in fusion plasmas in devices such as tokamaks and stellarators. The Grad-Shafranov equation, derived from ideal MHD, describes the equilibrium of axisymmetric toroidal plasma in a tokamak. In tokamak experiments, the equilibrium during each discharge is routinely calculated and reconstructed, providing information on the shape and position of the plasma controlled by currents in external coils. MHD stability theory governs the operational limits of tokamaks. For example, ideal MHD kink modes provide hard limits on the achievable plasma beta (Troyon limit) and plasma current (set by the
The human–animal bond can occur between people and domestic or wild animals; be it a cat as a pet or birds outside one's window. The phrase "Human-Animal Bond" or HAB began to emerge as terminology in the late 1970s and early 1980s. Research into the nature and merit of the human–animal bond began in the late 18th century when, in York, England, the Society of Friends established The Retreat to provide humane treatment for the mentally ill. By having patients care for the many farm animals on the estate, society officials theorized that the combination of animal contact plus productive work would facilitate the patients' rehabilitation. In the 1870s in Paris, a French surgeon had patients with neurological disorders ride horses. The patients were found to have improved their motor control and balance and were less likely to suffer bouts of depression. During the 1820s to 1870s, America's Victorian middle class used the human–animal bond to aid in children's socialization. This was an entirely gendered process, as parents and society believed only boys had an innate tendency towards violence and needed to be socialized towards kindness and empathy through companion animals. Over time pet-keeping to socialize children became more gender neutral, but even into the 1980s and 90s there remained a belief that boys especially benefited from pet-keeping due to the fact that it was one of only ways they could practice nurturing given the limiting gender norms. An example of the human–animal bond can be seen during World War I on the Western Front with horses.
American Chemical Society Award in Chromatography and Electrophoresis (1964) with Stanford Moore Richards Medal of the American Chemical Society (1972) with Stanford Moore Kaj Linderstrøm-Lang Award, Copenhagen (1972) with Stanford Moore The Nobel Prize in Chemistry (1972) with Stanford Moore and Christian B. Anfinsen
Sources: en.wikipedia.org
This is one reason why extreme intakes of any one single micronutrient are not advised. Individuals with chronic digestive problems may be unable to absorb sufficient amounts of copper, even though the foods they eat are copper-rich. Several copper transporters have been identified that can move copper across cell membranes. Other intestinal copper transporters may exist. Intestinal copper uptake may be catalyzed by Ctr1. Ctr1 is expressed in all cell types so far investigated, including enterocytes, and it catalyzes the transport of Cu+1 across the cell membrane. Excess copper (as well as other heavy metal ions like zinc or cadmium) may be bound by metallothionein and sequestered within intracellular vesicles of enterocytes (i.e., predominant cells in the small intestinal mucosa).
=== War in Yemen (2014–present) === Yemen was riven in 2015, with the Houthis establishing a new government in Sanaa and Hadi retreating with his supporters to Aden, and later Saudi Arabia. The Arab League, led by the Saudis, began a bombing campaign and mobilization of various armed forces in the region for a possible invasion.
== Function == This gene is a member of the glycoprotein hormone beta chain family and encodes the beta subunit of luteinizing hormone (LH). Glycoprotein hormones are heterodimers consisting of a common alpha subunit and a unique beta subunit (this protein) which confers biological specificity. LH is expressed in the pituitary gland and promotes spermatogenesis and ovulation by stimulating the testes and ovaries to synthesize steroids.
=== Pharmacogenetics === The predominant enzyme responsible for metabolism of tacrolimus is CYP3A5. Genetic variations within CYP3A5 that result in changes to the activity of the CYP3A5 protein can affect concentrations of tacrolimus within the body. In particular, individuals who are homozygous for the G allele at the single nucleotide polymorphism (SNP) rs776746 (also known as CYP3A5 *3/*3) have a non-functional CYP3A5 protein. The frequency of the G allele varies worldwide, from 4% in some African populations to 80–90% in Caucasian populations. Across a large number of studies, individuals homozygous for the G allele have been shown to have higher concentrations of tacrolimus and require lower doses of the drug, as compared to individuals who are not homozygous for the G allele. Achieving target concentrations of tacrolimus is important – if levels are too low, then there is a risk of transplant rejection, if levels are too high, there is a risk of drug toxicities. There is evidence to suggest that dosing patients based on rs776746 genotype can result in faster and more frequent achievement of target tacrolimus levels. However, there is a lack of consistent evidence as to whether dosing based on rs776746 genotype results in improved clinical outcomes (such as a decreased risk for transplant rejection or drug toxicities), likely because patients taking tacrolimus are subject to therapeutic drug monitoring. Studies have shown that genetic polymorphisms of genes other than CYP3A5, such as NR1I2 (encoding PXR), also significantly influence the pharmacokinetics of tacrolimus.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.